MONTREAL, QUEBEC–(Marketwired – Oct. 10, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017 in order to pursue other opportunities. Mr. Kadanoff served valiantly in this position since Knight became a publicly listed company in February 2014.
Effective immediately, Samira Sakhia, President of Knight, will assume the additional responsibility of CFO. Prior to joining Knight, Ms. Sakhia served as CFO of Paladin Labs Inc. for 14 years.
Jonathan Ross Goodman, Chief Executive Officer, said, “I will miss working with Jeffrey and wish him well. Having worked with Samira my entire 40s, I have seen the brightness of her star and am confident that her excellent track record and proven “can do” abilities will generate GUD shareholder value.”
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gudknight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2016. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.